{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:46:35Z","timestamp":1791229595244,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jfo.2026.104821","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T14:48:16Z","timestamp":1772549296000},"page":"104821","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Inflammations intraoculaires apr\u00e8s injection intravitr\u00e9enne d\u2019anti-VEGF de 2nde g\u00e9n\u00e9ration observ\u00e9es dans un centre tertiaire sur 12\u00a0mois\u00a0: quelles particularit\u00e9s\u00a0?"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-7160-1464","authenticated-orcid":false,"given":"A.","family":"Neyret","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9748-5440","authenticated-orcid":false,"given":"A.","family":"Moulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3663-8182","authenticated-orcid":false,"given":"S.","family":"Elbany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Gilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Chirpaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6239-4194","authenticated-orcid":false,"given":"A.","family":"Rocher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6948-5358","authenticated-orcid":false,"given":"S.","family":"Chacun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Billant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Fenniri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Matagrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4398-3978","authenticated-orcid":false,"given":"C.","family":"Dot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfo.2026.104821_bib0120","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","article-title":"TENAYA and LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2","volume":"131","author":"Khanani","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2026.104821_bib0125","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2026.104821_bib0130","doi-asserted-by":"crossref","first-page":"9424","DOI":"10.3390\/ijms23169424","article-title":"Aflibercept versus faricimab in the treatment of neovascular age-related macular degeneration and diabetic macular edema: a review","volume":"23","author":"Liberski","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jfo.2026.104821_bib0135","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.oret.2024.11.015","article-title":"Resolution of angiographic macular leakage with faricimab versus aflibercept in patients with diabetic macular edema in YOSEMITE\/RHINE","volume":"9","author":"Goldberg","year":"2025","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.jfo.2026.104821_bib0140","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.oret.2021.12.014","article-title":"Efficacy outcomes of brolucizumab versus aflibercept in neovascular age-related macular degeneration patients with early residual fluid","volume":"6","author":"Singh","year":"2022","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.jfo.2026.104821_bib0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.oret.2025.05.030","article-title":"TALON Phase IIIb Study: 32-week primary results of brolucizumab using treat and extend for neovascular age-related macular degeneration","volume":"9","author":"Regillo","year":"2025","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.jfo.2026.104821_bib0150","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ophtha.2024.08.022","article-title":"MERLIN: two-year results of brolucizumab in participants with neovascular age-related macular degeneration and persistent retinal fluid","volume":"132","author":"Brown","year":"2025","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2026.104821_bib0155","doi-asserted-by":"crossref","first-page":"5208","DOI":"10.3390\/jcm13175208","article-title":"Inflammation and vasculitis related to brolucizumab","volume":"13","author":"Campos","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.jfo.2026.104821_bib0160","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jamaophthalmol.2024.0530","article-title":"Severe intraocular inflammation following intravitreal faricimab","volume":"142","author":"Thangamathesvaran","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jfo.2026.104821_bib0165","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ajo.2024.08.008","article-title":"Severe intraocular inflammation after intravitreal injection of faricimab: a single-site case series of six patients","volume":"269","author":"Ben Ghezala","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2026.104821_bib0170","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1001\/jamaophthalmol.2024.0928","article-title":"Association of occlusive retinal vasculitis with intravitreal faricimab","volume":"142","author":"Li","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jfo.2026.104821_bib0175","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1001\/jamaophthalmol.2024.5889","article-title":"Inflammation and occlusive retinal vasculitis post faricimab","volume":"143","author":"Bruening","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jfo.2026.104821_bib0180","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1177\/2474126420975303","article-title":"Brolucizumab-associated intraocular inflammation in eyes without retinal vasculitis","volume":"5","author":"Witkin","year":"2021","journal-title":"J Vitreoretin Dis"},{"key":"10.1016\/j.jfo.2026.104821_bib0185","doi-asserted-by":"crossref","first-page":"101788","DOI":"10.1016\/j.ajoc.2022.101788","article-title":"Retinal arterial occlusive vasculitis after multiple intravitreal brolucizumab injections for diabetic macular edema","volume":"29","author":"Hirano","year":"2022","journal-title":"Am J Ophthalmol Case Rep"},{"key":"10.1016\/j.jfo.2026.104821_bib0190","series-title":"Communication orale SFO","article-title":"\u00c9tude SWIFT-HBP\u00a0: \u00e9valuation du switch vers le faricimab chez les patients atteints de DMLA \u00e0 haut fardeau th\u00e9rapeutique","author":"Simond","year":"2025"},{"key":"10.1016\/j.jfo.2026.104821_bib0195","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/IAE.0000000000003769","article-title":"Retinal vasculitis or vascular occlusion after brolucizumab for neovascular age-related macular degeneration: a systematic review of real-world evidence","volume":"43","author":"Wykoff","year":"2023","journal-title":"Retina"},{"key":"10.1016\/j.jfo.2026.104821_bib0200","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1177\/2474126420930863","article-title":"Occlusive retinal vasculitis following intravitreal brolucizumab","volume":"4","author":"Witkin","year":"2020","journal-title":"J Vitreoretin Dis"},{"key":"10.1016\/j.jfo.2026.104821_bib0205","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1186\/s12886-024-03788-w","article-title":"Aflibercept high-dose (8\u00a0mg) related intraocular inflammation (IOI) \u2013 a case series","volume":"24","author":"Hoffmann","year":"2024","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.jfo.2026.104821_bib0210","first-page":"e86113","article-title":"Recurrence of intraocular inflammation following an aflibercept 8-mg injection in eyes with a history of intraocular inflammation from faricimab: a case report","volume":"17","author":"Sato","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.jfo.2026.104821_bib0215","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10384-024-01107-w","article-title":"Retinal vasculitis after intravitreal aflibercept 8\u00a0mg for neovascular age-related macular degeneration","volume":"68","author":"Matsumoto","year":"2024","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.jfo.2026.104821_bib0220","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12886-024-03827-6","article-title":"Intraocular inflammation after intravitreal injection of aflibercept 8\u00a0mg for treatment-refractory neovascular age-related macular degeneration: a case report","volume":"25","author":"Hashiya","year":"2025","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.jfo.2026.104821_bib0225","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40942-021-00307-7","article-title":"Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review","volume":"7","author":"Anderson","year":"2021","journal-title":"Int J Retina Vitr"},{"key":"10.1016\/j.jfo.2026.104821_bib0115","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1001\/jamaophthalmol.2024.3828","article-title":"Sterile intraocular inflammation associated with faricimab","volume":"142","author":"Cozzi","year":"2024","journal-title":"JAMA Ophthalmol"}],"container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551226000471?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551226000471?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T17:41:03Z","timestamp":1774287663000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0181551226000471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0181551226000471"],"URL":"https:\/\/doi.org\/10.1016\/j.jfo.2026.104821","relation":{},"ISSN":["0181-5512"],"issn-type":[{"value":"0181-5512","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inflammations intraoculaires apr\u00e8s injection intravitr\u00e9enne d\u2019anti-VEGF de 2nde g\u00e9n\u00e9ration observ\u00e9es dans un centre tertiaire sur 12\u00a0mois\u00a0: quelles particularit\u00e9s\u00a0?","name":"articletitle","label":"Article Title"},{"value":"Journal Fran\u00e7ais d'Ophtalmologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfo.2026.104821","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104821"}}